Regeneron Pharmaceuticals, Inc.
All Topics
Find news about people
Find news on alumni of any org
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


Change Feed
Regeneron Pharmaceuticals, Inc.
... Regeneron, which was thinking its blockbuster eye drug Eylea would extend its market ...
... TARRYTOWN - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and bluebird bio, Inc. (NASDAQ: BLUE) today announced a ...
... the policy should benefit Mylan, as it encourages biosimilar adoption, but hurt Regeneron and Amgen within his team's coverage area. The changes stand to hurt ...
... Amgen made an aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the marketwhen the two were first duking it ...
... TARRYTOWN - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the winners of the sixth annual Regeneron Prize ...
... multi-center, open-label, dose escalation study testing the safety, durability, and tolerability of OTX-TKI.Regeneron collaboration continues for the development of OTX-IVT (aflibercept implant). The Company, along ...
... cancer therapies from the lab to patients, bluebird bio, of Cambridge, and Regeneron Pharmaceuticals, based in New York, announced Monday that they had reached a ...
Subscribe now for full coverage on Regeneron Pharmaceuticals, Inc.
Start My Free Trial